New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
HIGHER: AstraZeneca (AZN), up 16% after Pfizer (PFE) confirms takeover offer made and turned down by company. Pfizer shares are also up 2.7% as the company says it is still interested in a potential AstraZeneca combination and is weighing its next steps... Furiex (FURX), up 31% after agreeing to be acquired by Forest labs (FRX) for $95 per share and contingent future payments... Susser (SUSS), up 37% after agreeing to be acquired by Energy Transfer Partners (ETP) for approx. $1.8B... Agenus (AGEN), up 10% after announcing collaboration and license agreement with Merck (MRK)... Yokou Toudou (YOKU), up 10% after announcing $1.22B investment led by Alibaba... Corning (GLW), up 2.7% after earnings report. DOWN AFTER EARNINGS: (SOHU), down 6.6%... Haemonetics (HAE), down 9.5%... ALSO LOWER: Bank of America (BAC), down 2.6% after suspending capital actions, including repurchase authorization... Newmont Mining (NEM), down 5.7% after terminating merger discussions with Barrick Gold (ABX)... Athersys (ATHX), down 56% after MultiStem therapy trial fails to show meaningful benefit... OncoGenex (OGXI), down 52% after Synergy did not meet primary endpoint in Phase 3 trial... POZEN (POZN), down 12% after drug candidates PA8140/PA32540 receive Complete Response Letter from FDA.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
September 28, 2015
07:05 EDTETPWilliams Partners, Williams withdraw financial guidance
Subscribe for More Information
05:16 EDTOGXIOncoGenex announces results from Phase 3 trial of custirsen treatment
Subscribe for More Information
September 27, 2015
13:50 EDTBACBank of America likely to increase dividend, buyback plans, Barron's says
Subscribe for More Information
September 25, 2015
16:00 EDTBAC, PFEOptions Update; September 25, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 25.09. Option volume leaders: AAPL NFLX BAC FB AU NKE PFE INTC AMZN TSLA
13:03 EDTAGENAgenus management to meet with William Blair
Subscribe for More Information
09:34 EDTPFE, BACActive equity options trading on open
Active equity options trading on open: AAPL BAC FB NKE NFLX PFE AU TSLA
08:02 EDTGLWCorning coverage assumed with a Neutral at Goldman
Subscribe for More Information
07:54 EDTABXBarrick Gold says Veladero processing restrictions lifted
Barrick Gold announced that restrictions on processing activities at the Veladero mine in San Juan province, Argentina, have been lifted. A local court previously restricted the addition of new reagents to the mine's heap leach circuit following the failure of a valve on a pipe carrying cyanide solution at the leach pad, which led to a release of solution. Barrick does not anticipate any material impact to production at Veladero as a result of this incident.
07:22 EDTPFE, AZNEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
07:03 EDTPFEMerck KGaA, Pfizer announce FDA orphan drug designation for avelumab
Subscribe for More Information
05:08 EDTPFEStocks with implied volatility movement; PFE HLF
Subscribe for More Information
September 24, 2015
17:04 EDTPFEMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information
16:00 EDTBACOptions Update; September 24, 2015
Subscribe for More Information
07:33 EDTPFEBIND says Pfizer exercises option to obtain license for Accurin drug candidate
BIND Therapeutics (BIND) announced that Pfizer (PFE) exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors under the companies' global collaboration agreement. The actively targeted Accurin is designed to impart cellular targeting capability and was engineered by BIND using one of Pfizer's proprietary kinase inhibitors and one of BIND's proprietary ligands. As a result of the option exercise, BIND will receive a $2.5 million option exercise fee from Pfizer. In parallel with exercising its first option, Pfizer informed BIND that it will not exercise its option for the second compound in the collaboration. Under terms of the original collaboration agreement, which was established in April 2013, Pfizer was granted options to obtain exclusive licenses to pursue development and commercialization of two Accurins that incorporate specified Pfizer small molecular targeted therapies. For the Accurin that has been selected, both companies will work together on preclinical research; Pfizer will have responsibility for development and commercialization, and BIND will conduct chemistry, manufacturing and control activities. In addition to the $2.5 million option exercise fee, BIND received an upfront payment of $4.0 million in 2013 and achieved a $1.0 million preclinical development milestone for the selected Accurin in December 2014. BIND has the potential to receive additional milestone payments for the selected Accurin of up to $86.0 million in aggregate upon the achievement of additional specified development and regulatory events under the Pfizer collaboration agreement. BIND may also receive additional milestone payments for the selected Accurin of up to $110 million in aggregate for specified commercial events as well as royalties in the low single to high single digit percentages on potential future sales of the selected Accurin, if any.
07:10 EDTBACBanks clash with regulators over energy lending, WSJ reports
Banks are fighting with regulators over loan reviews that might compress the flow of net credit to the oil patch, the Wall Street Journal reports. The disagreement is focused on the narrow issue of loans secured by oil and gas companies' reserves, but it highlights the point of how postcrisis regulation of the financial industry impacts sectors outside of Wall Street, the report says. Caught in between banks and regulators are the small and medium exploration and production companies that rely on credit lines using their energy reserves as collateral, the report says. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
September 23, 2015
16:00 EDTBACOptions Update; September 23, 2015
iPath S&P 500 VIX Short-Term Futures down 53c to 23.81 Option volume leaders: AAPL NFLX BAC FB BABA DOW RIG MU FCX PBR XOM JPM
09:09 EDTOGXIOn The Fly: Pre-market Movers
HIGHER: Heron Therapeutics (HRTX), up 20% after announcing results from its Phase 2 clinical study of its drug for the management of post-operative pain in patients undergoing bunionectomy... BioMed Realty Trust (BMR), up 10% after Bloomberg reported that the company is in talks to sell itself and has attracted interest from companies including Blackstone (BX) and Canaccord upgraded BioMed Realty to Buy... Citrix Systems (CTXS), up 2.5% after Reuters said the company is making a last-ditch attempt to sell itself as a whole company before beginning asset sales. LOWER: OncoGenex (OGXI), down 19% after the company reported that the addition of apatorsen to Abraxane and gemcitabine did not demonstrate a survival benefit compared to Abraxane and gemcitabine alone in a Phase 2 clinical study... Pacira Pharmaceuticals (PCRX), down 3.7% in the wake of Heron's new data, with several analysts stating that Heron's data compares favorably versus Pacira's Exparel drug.
07:08 EDTOGXIOncoGenex's Phase 2 Rainier study for pancreatic cancer did not show benefit
OncoGenex announced initial results from the Phase 2 Rainier study evaluating apatorsen in combination with Abraxane and gemcitabine compared to Abraxane and gemcitabine alone in patients with untreated metastatic pancreatic cancer. The addition of apatorsen to Abraxane and gemcitabine did not demonstrate a survival benefit compared to Abraxane and gemcitabine alone. The most common grade 3/4 treatment-related toxicities on the apatorsen arm were anemia, neutropenia and fatigue, also consistent with the chemotherapy regimen side effects. These and other adverse events observed on the apatorsen arm were similar to those seen in previous trials, with the exception of an increase in grade 4 or greater AEs and serious AEs in this pancreatic cancer trial.
05:32 EDTPFEViiV Healthcare announces Triumeq Phase IIIb study met primary endpoint
Subscribe for More Information
05:10 EDTGLWStocks with implied volatility movement; GLW WMB
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use